Extens supports Kayentis in its expansion in the United States

Back Published on 28/03/2023

Extens, the growth investor in digital health, the growth investor in digital health, supports Kayentis in expanding its activities in the United States by participating in additional financing.

This additional financing comes within just one month after signing a strategic alliance with ClinOne, a US-based solutions provider of adaptive clinical trial experiences for patients, families, and clinical sites.

As a long-standing shareholder of Kayentis, Extens contributes to its strengthening by reinvesting alongside its co-investors LBO France and Bpifrance, after having accompanied the company through all the critical stages of its development. The previous operation, carried out in 2020, enabled the launch of the ClinForm3 platform - centered on the patient – to place the company at the top of the global market.

« Kayentis has undergone a spectacular evolution since we first invested. Guillaume Juge and his management team have transformed the company into a renowned global player in digital clinical trials. Once again, we are fully confident in the team’s aims for US market growth and in accelerating the development of its global clinical trial management solution for decentralised clinical trials. »

Cédric BERGER